XTalks

AUGUST 14, 2024

The approval marks a huge milestone for nemolizumab, which recently demonstrated significant itch-relief in clinical trials last month in adolescent and adult patients with moderate-to-severe atopic dermatitis. A significant percentage of patients also reported reduced sleep disturbances by Week 16 in both clinical trials.

Drug Delivery Systems 111

Drug Delivery Systems Dermatology Drug Delivery Antibody 111

XTalks

SEPTEMBER 30, 2024

Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, the study highlighted significant improvements in key disease markers, positioning orismilast as a potential breakthrough in atopic dermatitis management.

Clinical Trials 98

Clinical Trials Clinical Trials Dermatology Trials 98

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

APRIL 17, 2023

In clinical trials, patients experienced significantly clearer skin and less interference with sleep due to itch when taking lebrikizumab compared to placebo. The ADvocate1 and ADvocate2 Phase III studies were published in the New England Journal of Medicine and the British Journal of Dermatology , respectively.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

XTalks

JUNE 20, 2022

The results of their Phase IIa STP705 clinical study were published in the Journal of Drugs in Dermatology , a peer-reviewed medical journal of dermatology that was established in 2002. Clinical Trial Outcomes of isSCC Treatment with STP705. STP705 — A Promising siRNA Candidate Against isSCC.

RNA 96

RNA Clinical Trials Clinical Trials Dermatology 96

XTalks

JUNE 26, 2024

Hyperhidrosis is the third most prevalent dermatological condition in the US, affecting roughly 15.3 The Impact of Hyperhidrosis on Quality of Life Hyperhidrosis has profound effects on mental health , self-esteem, social interactions, relationships and occupational choices. million people, following acne and atopic dermatitis.

Clinical Trials 103

Clinical Trials Clinical Trials Dermatology FDA Approval 103

XTalks

MARCH 24, 2023

The company recently presented a pooled analysis from clinical studies of their DermaSensor skin cancer detection device at the American Academy of Dermatology (AAD) 2023 Annual Meeting. The results presented were from two of DermaSensor’s four clinical studies that were submitted to the US Food and Drug Administration (FDA).

Dermatology 97

Dermatology Clinical Trials Clinical Trials Sales 97

XTalks

MAY 31, 2022

XTALKS WEBINAR: All Means All: The Road to Inclusivity in Clinical Trials. Register for this free webinar to learn what the FDA’s new draft guidance means for diverse and inclusive trials. Clinical Trials of Vtama. At Dermavant, we are committed to advancing novel, patient-focused innovation in immuno-dermatology.

FDA Approval 98

FDA Approval Clinical Trials Clinical Trials Trials 98

XTalks

AUGUST 2, 2024

These trials reveal nemolizumab’s potential to significantly improve key aspects of atopic dermatitis, including skin lesions, itch and sleep disturbance, in both adolescent and adult patients with moderate-to-severe cases.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Licensing 52

XTalks

MAY 23, 2024

For healthcare and life sciences industries, Skin Cancer Awareness Month helps highlight the importance of preventive measures and early detection. Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays.

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

XTalks

AUGUST 7, 2023

Verrica, a company specializing in dermatology therapeutics, has designed Ycanth to be delivered through a single-use applicator. Efficacy and Safety of Ycanth The effectiveness of Ycanth was evaluated in two randomized, double-blind, placebo-controlled Phase III clinical trials, identified as Trial 1 and Trial 2.

FDA Approval 98

FDA Approval Dermatology Trials Clinical Trials 98

XTalks

JULY 31, 2024

Leqselvi’s approval is based on data from two Phase III clinical trials, THRIVE-AA1 and THRIVE-AA2, which together enrolled over 1,200 patients. Leqselvi works by selectively inhibiting the Janus kinases (JAK) JAK1 and JAK2, pathways that play a key role in this misguided immune response.

Immune Response 105

Immune Response Dermatology Clinical Trials Clinical Trials 105

XTalks

DECEMBER 15, 2020

Synteract has a solid reputation in the emerging biopharma sphere, providing therapeutic expertise in areas including oncology, rare and orphan diseases, neuroscience, dermatology and pediatrics. Synteract’s client base largely consists of pre-revenue companies, a segment in which Syneos Health sees growth opportunities for itself.

Dermatology 98

Dermatology Clinical Trials Clinical Trials Branding 98

XTalks

SEPTEMBER 14, 2022

Daxxify is effective, as safe as competitors, and has been well tolerated in clinical trials. The approval of Daxxify was based on data generated in a series of clinical trials, the SAKURA Phase III clinical trial program ( 1 , 2 and 3 ). A Novel Botox Competitor. Bringing Daxxify into Offices.

Botox 98

Botox FDA Approval Cosmetics Clinical Trials 98

XTalks

MAY 22, 2023

It’s an extremely important factor I consider in my therapeutic process of restoring their natural beauty and appearance,” said Macrene Alexiades, MD, PhD, dual US-EU board-certified dermatologist, SkinVive by Juvéderm lead investigator and author of the clinical trial published in Dermatologic Surgery.

Filler 92

Filler FDA Approval Dermatology In-Vivo 92

XTalks

JUNE 17, 2024

RELATED: Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan Aesthetics – Xtalks Life Science Podcast Ep. 134 How Does Letybo Work?

FDA Approval 52

FDA Approval Marketing Botox Clinical Trials 52

XTalks

SEPTEMBER 22, 2022

Clinical Trial Behind Spevigo. The efficacy of Spevigo (spesolimab) was determined based on the results of the Effisayil 1 double-blind, randomized, Phase II clinical trial. Waldman Department of Dermatology. Spevigo is the first approved treatment option for GPP in adults.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Dermatology 52

XTalks

SEPTEMBER 24, 2024

The FDA approval is based on data gathered in three pivotal Phase III clinical trials: ADvocate 1, ADvocate 2 and ADhere. Ebglyss’ clinical trial side effects were mostly manageable but included eye inflammation, injection site reactions and shingles.

Clinical Trials 52

Clinical Trials Clinical Trials FDA Approval Trials 52

XTalks

JANUARY 2, 2024

The clinical study also highlighted the favorable tolerability profile of Filsuvez. The most commonly reported adverse reactions in the clinical trial were pruritus (itching) and pain at the wound application site, occurring in 7.3 Specifically, 41.3 percent observed in the control gel arm. percent of cases.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

XTalks

DECEMBER 15, 2020

Synteract has a solid reputation in the emerging biopharma sphere, providing therapeutic expertise in areas including oncology, rare and orphan diseases, neuroscience, dermatology and pediatrics. Synteract’s client base largely consists of pre-revenue companies, a segment in which Syneos Health sees growth opportunities for itself.

Dermatology 52

Dermatology Clinical Trials Clinical Trials Branding 52

XTalks

JUNE 10, 2024

When psoriasis gets really bad, it’s really hard to get up again,” shared popstar Cindy Lauper in an interview with the American Academy of Dermatology Association. The approval of Sotyktu was based on robust data from the pivotal POETYK PSO-1 and POETYK PSO-2 Phase III clinical trials. More About Psoriasis About 7.55

Immune Response 52

Immune Response Dermatology Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 5, 2024

Related: Nemolizumab Delivers Significant Itch-Relief in Phase III Clinical Trials The Opzelura commercial underscores the growing prominence of the topical cream in treating mild to moderate atopic dermatitis and vitiligo. The initial FDA approval for atopic dermatitis paved the way for the 2022 FDA approval for vitiligo.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Containment 52

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. billion ($3.65 billion ($2.85

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JANUARY 12, 2024

The FDA’s approval of Zelsuvmi was based on data from two Phase III clinical trials, B-SIMPLE 4 and B-SIMPLE 2, involving 1,598 patients. However, the exact mechanism of action of Zelsuvmi in its treatment of molluscum contagiosum is unknown, said Ligand.

FDA Approval 64

FDA Approval Trials Clinical Trials Clinical Trials 64

XTalks

DECEMBER 14, 2023

However, its uses expanded over the years into other indications, ranging from parasitic infection to dermatology. In a statement , USWM said it partnered with the Beat Childhood Cancer Research Consortium at Penn State University, which “conducted the preclinical and clinical research to help advance this vital therapy.

FDA Approval 52

FDA Approval Dermatology Drugs DNA 52

The Pharma Data

JANUARY 26, 2021

Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan® (favipiravir) for the worldwide treatment and prevention of COVID-19.

Life Science 40

Life Science Production Marketing Dermatology 40

XTalks

JUNE 14, 2021

Related: Google Launches AI-Based Dermatology Assist Tool. Testing is limited to laboratories designated by STS Lab Holdco to be certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263, and meet the requirements to perform high-complexity tests.

Biohazard 59

Biohazard Biohazard Dermatology Clinical Trials 59

XTalks

DECEMBER 18, 2024

The approval was based on findings from pivotal Phase I and Phase II clinical trials, which demonstrated significant response rates and a favorable safety profile in patients with advanced cSCC.

FDA Approval 95

FDA Approval Antibody Immune Response Marketing 95

XTalks

JANUARY 2, 2025

Why it sold so well: Skyrizi, an interleukin-23 (IL-23) inhibitor, has shown clinical efficacy in treating moderate-to-severe plaque psoriasis and active psoriatic arthritis. Skyrizis targeted mechanism of action and long-lasting effectiveness have positioned it as a leading choice among modern biologics in dermatology.

Sales 85

Sales FDA Approval Drugs Marketing 85